Macquarie Stem Cells has provided this information to educate the public based on peer reviewed, published scientific and medical documents. We don’t aim to encourage consumers to seek out such treatments prior to an assessment by a health professional to determine your suitability for treatment. This is obtained directly from NCBI Pubmed Literature. This research was undertaken, in part, thanks to funding from the Canadian Institutes of Health Research. We aim to provide you with an unbiased range of treatments that are available aside from biological therapy, this is discussed in ‘supporting information>other-options’ page on our website.
Published: BMJ (Biomedical Journal) – 2016
“To determine the cost–effectiveness of arthroscopic surgery in addition to non-operative treatments compared with non-operative treatments alone in patients with knee osteoarthritis (OA).” (Marsh J., et al, 2016)
“We conducted an economic evaluation alongside a single-centre, randomised trial among patients with symptomatic, radiographic knee OA (KL grade ≥ 2).” (Marsh J., et al, 2016)
“Patients received arthroscopic debridement and partial resection of degenerative knee tissues in addition to optimised non-operative therapy, or optimised non-operative therapy only.” (Marsh J., et al, 2016)
“Direct and indirect costs were collected prospectively over the 2-year study period. The effectivenessoutcomes were the Western Ontario McMaster Osteoarthritis Index (WOMAC) and quality-adjusted life years (QALYs). Cost–effectivenesswas estimated using the net benefit regression framework considering a range of willingness-to-pay values from the Canadian public payer and societal perspectives. We calculated incremental cost–effectiveness ratios and conducted sensitivity analyses using the extremes of the95% CIs surrounding mean differences in effect between groups.” (Marsh J., et al, 2016)
“168 patients were included. Patients allocated to arthroscopy received partial resection and debridement of degenerative meniscal tears (81%) and/or articular cartilage (97%). There were no significant differences between groups in use of non-operative treatments. Theincremental net benefit was negative for all willingness-to-pay values. Uncertainty estimates suggest that even if willing to pay $400,000 to achieve a clinically important improvement in WOMAC score, or ≥$50,000 for an additional QALY, there is <20% probability that the addition of arthroscopy is cost-effective compared with non-operative therapies only. Our sensitivity analysis suggests that even when assuming thelargest treatment effect, the addition of arthroscopic surgery is not economically attractive compared with non-operative treatments only.” (Marsh J., et al, 2016)
“Arthroscopic debridement of degenerative articular cartilage and resection of degenerative meniscal tears in addition to non-operative treatments for knee OA is not an economically attractive treatment option compared with non-operative treatment only, regardless of willingness-to-pay value.” (Marsh J., et al, 2016)
REF: Marsh, J., Birmingham, T., Giffin, J., Isaranuwatchai, W., Hoch, J., Feagan, B., Litchfield, R., Willits, K. and Fowler, P. (2016). Cost-effectiveness analysis of arthroscopic surgery compared with non-operative management for osteoarthritis of the knee. BMJ Open, 6(1), p.e009949.
Tags: Macquarie Stem Cells, Dr. Bright, Osteoarthritis Treatment, Dr. Ralph Bright, Joint Arthroscopies, Arthro surgery, arthroscopic surgery, cost of arthroscopy
Remember, any surgical or invasive procedure carries risks. Before proceeding, you should seek a second opinion from an appropriately qualified health practitioner.